علاج الاعتلال الوعائي الشبكي عند وجود أضداد الفوسفولبيد (متلازمة أضداد الفوسفولبيد)

If antiphospholipid antibodies are present, DOAC should not be used since treatment with rivaroxaban in patients with antipospholipid syndrome has been shown to increase the risk of recurring thrombotic events.

Treatment with low-molecular-weight heparin should be initiated at the full therapeutic dose (for example enoxaparin 1 mg/kg BW subcutaneously twice a day in the morning and evening (off label)).

Once findings are stable, dosage should be reduced to a semi-therapeutic level (for example enoxaparin 1 mg/kg BW subcutaneously once a day (off label)).

The time lag between initiation of treatment or increasing the dose and the resulting pain relief is 2–4 days, so the therapeutic response can be assessed rapidly.